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Atrial fibrillation is common supraventricular arrhythmia associated with arterial 
hypertension. The mechanisms that affect arterial hypertension causing atrial fibrillation 
are various and include: left ventricular hypertrophy, myocardial ischemia, left ventricle 
impaired function and left atrial enlargement. 
The aim of the study was to determine the size of the left atrium in paroxysmal atrial 
fibrillation and arterial hypertension patients. 
The investigation comprised a group of 117 paroxysmal atrial fibrillation  patients. Of  
this number, 87 patients had arterial hypertension, and 30 patients were without arterial 
hypertension and other disorders and diseases (LONE). 
The arterial hypertension patients were divided into 3 groups: the arterial 
hypertension patients, those without left ventricular hypertrophy and without ischemia; 
the arterial hypertension patients, those with left ventriclular hypertrophy but without 
ischemia and the arterial hypertension patients with concomitant ischemic heart disease. 
The patients without arterial hypertension and other disorders and diseases (LONE) 
represented the fourth group. 
The size of the left atrium was recorded by echocardiography. The highest average left 
atrium size value was found in the arterial hypertension patients, those with concomitant 
ischemic heart disease and it was 43,39 mm;  in the arterial hypertension patients with 
left ventricular hypertrophy but without ischemia, it amounted to 39,85 mm. The average 
left atrium size value in arterial hypertension patients, those without left ventricular 
hypertrophy and without ischemia was 37,24 mm, and the lowest average left atrium size 
value was documented in the patients without arterial hypertension (LONE) and it was 
34,61 mm. 
Of this number, 80.95% of arterial hypertension patients, those with concomitant 
ischemic heart disease, as well as 45.45% of arterial hypertension patients with left 
ventricular hypertrophy and without ischemia had the enlarged left atrium. The patients 
without arterial hypertension (LONE) did not have the enlarged left atrium. 
It may be concluded that the left atrium size in the arterial hypertension patients in 
the presence of left ventricular hypertrophy, and especially with the concomitant ischemic 
heart disease, represents a significant prerequisite for paroxysmal atrial fibrillation 
genesis. The highest percentage of the patients with enlarged left atrium in the group with 
arterial hypertension and concomitant ischemic heart disease proves that the ischemic 
heart disease is the most common arrhythmic factor. Left ventricular hypertrophy 
immediately follows  ischemic heart disease. Acta Medica Medianae 2008;47(3):9-14. 
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Introduction 
 
Atrial fibrillation is the most common sustained 
cardiac arrhythmia which is characterized by the 
uncoordinated atrial activity with the consequent 
loss of atrial mechanical function (1). 
In the wide spectrum of etiologic factors, 
arterial hypertension and ischemic heart disease 
play the leading role (2). 
Arterial hypertension can lead to atrial 
fibrillation due to the left atrial dilatation, and/or 
increased inatrial pressure which comes out of 
decreased left ventricular compliance, and 
ischemia, especially in hypertensive subjects with 
left ventricular hypertrophy (3). 
Arterial hypertension is an important risk 
factor for  ischemic heart disease. Left ventricular 
hypertrophy is an independent risk factor in   
ischemic heart disease, while myocardial ischemia is 
the most common arrhythmic factor (4,5).  
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Aims 
 
The aim of the study was to determine the 
left atrium size in the paroxysmal atrial fibri-
llation and arterial hypertension patients. The 
influences of left ventricular hypertrophy as well 
as concomitant ischemic heart disease on the left 
atrium size in arterial hypertension patients were 
taken into consideration, as well as the 
significance of the left atrium size in the genesis 
of paroxysmal atrial fibrillation. 
 
Material and methods 
 
The research was carried out on a group of 
117 paroxysmal atrial fibrillation patients. Out of 
this number, 87 patients had arterial hype-
rtension (74,36%) and 30 patients were without 
arterial hypertension and other disorders and 
diseases (LONE) (25,64%). 
The group of arterial hypertension patients 
concerning either the presence of left ventricular 
hypertrophy and myocardial ischemia or their 
absence was divided into 3 subgroups: 
I.  The arterial hypertension patients, those 
without left ventricular hypertrophy and 
without ischemia - 21 (17.95%) patients. 
II.  The arterial hypertension patients, those with 
left ventricular hypertrophy but without 
ischemia - 22 (18,80%) patients. 
III. The arterial hypertension patients with 
concomitant ischemic heart disease - 44 
(37,61%) patients. 
The patients without arterial hypertension 
and other disorders and diseases (LONE) 
represented the IV group 30 (25,64%) (Graph 1). 
 
Graph 1. Structure of the tested groups of patients 
with paroxysmal atrial fibrillation 
 
Echocardiography was performed in all 
patients thanks to HP device 2500 Sonos. 
The presence of left ventricular hypertro-
phy was estimated using the ultrasound scanner 
method. The criterion used for the left ventricular 
hypertrophy was the thickness of the intra-
ventricular septum that was measured using the 
M-mode technique of 11 mm or even more. 
The presence of myocardial ischemia was 
estimated using the exercise test on ergobicycle. 
The patients with positive exercise test had 
a stable form of angina pectoris.  
The criterion for the positive exercise test 
was the depression of ST segment of horizontal 
or descending type that was either equal to or 
greater than 1 mm (0,1 mV) lasting for at least 
0.08 s.  
The left atrium size was measured using 
the M-mode ultrasound scanner technique with 
the longitudinal parasternal section according to 
ASE association references. 
The criterion for the left atrium enlargement 
was the left atrium size greater than 40 mm. 
The analyzed group was the group with the 
paroxysmal atrial fibrillation and without arterial 
hypertension. 
Ischemic heart disease in our research     
included steady angina pectoris, unsteady angina 
pectoris and recovered myocardial infarction. 
The research was carried out in the Emerge-
ncy Medical Service, Health Centre  Leskovac.  
 
Results  
 
The research was carried out on a group of 
117 paroxysmal atrial fibrillation patients (Graph 1). 
The average age of the arterial hyperte-
nsion patients was 60,61 ± 9,81 years. 
The average age of the patients with arterial 
hypertension among groups was the following: 
the first group - 58,62±11,70 years; the second 
group - 57,82±11,18 years; the third group - 
62,95±7,49 years. 
The average age of the patients without 
arterial hypertension (LONE) was 50,53 ± 11,92 
years. 
The arterial hypertension patients were 
significantly older than the patients without 
arterial hypertension (LONE) (p<0,001). 
Using the Student's t-test for independent 
samples,  a statistically significant difference 
between the third and the fourth group of 
patients was established (p<0,001).  
In the group of arterial hypertension 
patients, 41 (47,13%) subjects were male with 
the average age of 58,88 ± 11,48 years, and 46 
(52,87%) subjects were female with the average 
age of 62,15 ± 7,84 years. 
In the group of patients without arterial 
hypertension (LONE), 20 (66,67%) subjects were 
males with the average age of 48,45 ± 12,31 
years, and 10 (33,33%) subjects were females 
with the average age of 54,70 ± 10,41 years. 
According to statistics, there was not a 
significant difference concerning the age of both 
sexes in these groups. 
 
Table 1. Aaverage duration of arterial hypertension 
(the age) in the analyzed groups 
 
Group  X SD  N  CV  95%  CI 
I 12,90 
b* 8,91 21  69,05  8,85 16,96 
II 8,05  5,92 22  73,53  5,42 10,67 
III 14,52 
b*** 8,65 44 59,56 11,89 17,15 
ANOVA: F=4,70, p=0,0116 
 
b – towards the second (II) group  
* - p<0.05, 
*** - p<0.001 
 
The average duration of arterial 
hypertension considering the age in the following 
groups of patients was the following: in the first 
group of patients with arterial hypertension and 
without left ventricular hypertrophy as well as 
without ischemia the duration was 12,90±8,91 Acta Medica Medianae 2008,Vol.47                                        The size of the left atrium in patients with paroxy... 
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yeras; in the second group of patients with arterial 
hypertension,  left ventricular hypertrophy but 
without ischemia it was 8,05±5,92 years, and in 
the third group of patients with arterial hyper-
tension and concomitant ischemic heart disease it 
was 14,52±8,65 years (Table 1). Thus, statistically 
significant difference in arterial hypertension dura-
tion among groups was established (p<0,05). 
This is certainly the consequence of significantly 
longer arterial hypertension duration considering 
statistics in the third and the first group 
compared with the second group of patients 
(Using the Student's t-test, p<0,01; p<0,05, 
respectively).   
The arterial hypertension patients had the 
average left atrium size value of 40,95±5,07 mm, 
which is considered to be statistically higher ave-
rage value than in the patients without arterial hy-
pertension (LONE) (χ
2 = 5.26, p<0.001) (Table 2). 
 
Table 2.  Left atrium size (in mm) in the tested groups 
of patients 
 
Group X SD  N  CV  95%  CI 
I 37.24 
d* 3.87  21  10.40 35.48 39.00 
II 39.85
d*** 4.67  22  11.72 37.78 41.93 
III 43.39
b**.ad***  4.53 42  10.43 41.98 44.80 
IV 34.61  4.40  21  12.72 32.61 36.61 
The Anova analysis: F=21.30. p=0.0000 
a - to I. 
b - to II. 
d - to IV group 
* - p<0.05. ** - p<0.01. *** - p<0.001 
 
Comparing the groups one by one using the 
Student's t-test, it was established that the 
largest average left atrium size value was in the 
group III with arterial hypertension patients and 
concomitant ischemic heart disease (43,39 mm), 
and it was statistically higher compared with the 
II group of arterial hypertension patients, those 
with left ventricular hypertrophy and without 
ischemia (39,85 mm) (p<0,01),  and with the I 
group with arterial hypertension patients, those 
without left ventricular hypertrophy and without 
ischemia (37,24 mm) and IV group of the 
patients without arterial hypertension (LONE) 
(34,61 mm) (p<0,001). Compared with the IV 
group of patients without arterial hypertension 
(LONE), which has the lowest average value of 
this parameter, both I group (p<0,01) and II 
group of patients (p<0,001) had statistically 
higher values (Table 2).  
According to the ANOVA analysis statistics, 
it was shown that the medium values of the left 
atrium size differed significantly (p<0,001). The 
coefficient of variation showed the homogeneity 
of all groups concerning this parameter (Table 2).  
The enlarged left atrium was documented 
in 49 patients, which was over 40% (42,61%) of 
all patients, and that was 57,65% of arterial 
hypertension patients. Thanks to the Hi square 
test it was confirmed that the groups   completely 
differed in the frequency of enlarged left atrium 
finding (χ
2=50,63, p<0,001) (Table 3).   
While in the IV group of the patients without 
arterial hypertension (LONE) the left atrium 
enlargement was not detected, the same was 
detected, even in higher percentage, in the patients 
of group III, those with arterial hyper-tension and 
concomitant ischemic heart disease (80,95%), 
which was statistically more significant  compared 
with the II group with arterial hypertension, left 
ventricle hypertrophy and without ischemia 
(45,45%) (p<0,01) and the group I with arterial 
hypertension but without left ventricular hyper-
trophy and without ischemia (23,81%) (p<0,001) 
(Table 3). 
 
Table 3.  Enlarged left atrium in the tested groups of patients 
 
Group
Enlarged left 
atrium 
Without  left atrium 
enlargement 
I 5  23,81%  16  76,19% 
II 10  45,45%  12  54,55% 
III 34  80,95%  8  19,05% 
IV 0  0,00% 30  100,00% 
Total 49  42,61%  66  57,39% 
 
The repetition of attacks was the most 
frequent in the patients from the third group, 
those with arterial hypertension and concomitant 
heart disease - 72,73%, which was, according to 
statistics, significantly higher when  compared to 
the patients from group IV, those without arterial 
hypertension - 33,33% (p<0,01) and group I   
with arterial hypertension but without left 
ventricular hypertrophy and without ischemia- 
19,05% (p<0,001). Fifty percent of the patients 
from the second group, those with arterial 
hypertension, left ventricular hypertrophy and 
without ischemia sustained  repeated attacks 
(Table 4). 
 
Table 4. Number and percentage of patients with 
repeated series of PAF in the course of the following 
year from the moment of the current attacks by groups 
 
Group    
I 4  19,05% 
II 11  50,00% 
III 32
d**, a***  72,73% 
IV 10  33,33% 
Total 57  48,72% 
a - to I, 
d - to IV group 
** - p<0,01, 
*** - p<0,001 
 
Discussion  
 
In the past, atrial fibrillation was consi-
dered to be an insignificant condition, but now it 
is increasingly recognized that atrial fibrillation 
finding makes an independent contribution to 
mortality, morbidity and worsened life quality (6). 
Atrial fibrillation is the most frequent, clinically 
important arrhythmia that approximately 1,0-
1,5% of the world population suffer from, and 
thus it is anticipated that by 2050, some 15,9 
millions of people in the USA will have certain 
problems with it (6).  
These data stand for a kind of warning of 
the “epidemical time bomb” that the physicians 
of the future should await. 
Atrial fibrillation is certainly the “epidemic” 
nowadays (6). 
Due to many studies of the world population, 
arterial hypertension is the most common etiologic 
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In our research, out of 117 paroxysmal atrial 
fibrillation patients, 87(74,36%) patients with 
average age of 60,61 ± 9,81 years had arterial 
hypertension. Out of it, as well, 30 patients 
(LONE) (25,64%) with average age of 50,53 ± 
11,92 years did not suffer from arterial hyper-
tension. The results of the Euro Heart Survey 
studies on atrial fibrillation, which included 5,333 
atrial fibrillation patients in 35 countries in 
Europe, with the objective to confirm funda-
mental clinical characteristics of atrial fibrillation 
patients and the adjustment of atrial fibrillation 
therapy to the valid recommendations, published 
for the first time in October in 2005, showed that 
arterial hypertension was the most frequently 
joined with atrial fibrillation, then heart failure 
and coronary disease (8). 
Arterial hypertension is associated with the 
left atrium structural changes associated with 
atrial fibrillation. They include left atrium enla-
rgement, the left atrium changes in mechanical 
function, the left atrium electrophysiological changes 
and the increase of the left atrium ectopic activity (9). 
The left atrium enlargement is a significant 
phase in the progression from arterial hypertensi-
on to atrial fibrillation.  
Our results point to the influence of arterial 
hypertension on the left atrium enlargement in 
paroxysmal atrial fibrillation patients. 
Thanks to the Framingham Heart study,  it 
was shown that the left atrium enlargement could 
be associated with the duration  of hypertension 
and with the degree of systolic blood pressure in 
general population (10). 
In our research, the statistically significant 
difference in the duration of arterial hypertension 
considering the age of patients with arterial 
hypertension and concomitant ischemic heart 
disease was established, as well as in the 
patients who had arterial hypertension but were 
without left ventricle hypertrophy and without 
ischemia compared to the group of patients with 
arterial hypertension, left ventricular hypertrophy 
but without ischemia.   
Whether the left atrium size enlargement in 
arterial hypertension is a direct result of the 
arterial hypertension or a result of the underlying 
left ventricular hypertrophy and subsequent 
diastolic dysfunction is still not quite clear. 
The left atrium size is significantly greater 
in arterial hypertension patients compared with 
the patients with normal blood pressure (11). 
In our research, according to the statistics, 
arterial hypertension patients have significantly 
higher average value of the left atrium size 
compared with the patients without arterial 
hypertension (LONE). 
The left atrium size also correlates with left 
ventricular hypertrophy and diastolic dysfunction 
(11). 
The average left atrium size in the group of 
arterial hypertension patients, left ventricle hyper-
trophy and without ischemia is greater than the 
average left atrium size in the group with arterial 
hypertension but without left ventricular hypertrophy 
and without ischemia. 
Our finding confirms the positive correlation 
between left ventricular hypertrophy and the left 
atrium size. 
During diastole, except in the period of 
isovolumetric relaxation, the left atrium is exposed 
to the direct left ventricular pressure through the 
open mitral valve. Because of the left ventricular 
wall thickening in the patients with hypertensive 
heart disease, left ventricle’s filling in diastole is 
worsened, and as a result of the blood flow from 
the left atrium to the left ventricle is worsened 
(11,12).  
Taking into consideration that the left 
atrium has thin walls, it widens, its size becomes 
greater depending as well on the left atrium 
pressure increase. Thus, the left atrium enlarge-
ment is probably the result of the left atrium 
chronic high pressure, so that  echocardiographic 
enlargement of the left atrium is an early sign of 
hypertensive heart disease (11). 
This finding is supported by the presence of 
the enlarged left atrium in electrocardiograph and/ or 
echocardiography even before the develo-pment of 
the apparent left ventricular hypertrophy (11). 
Some studies show that 21% of the hyper-
tensive patients without electrocardiographic 
proofs of the left ventricular hypertrophy had the 
enlarged left atrium over 4 cm (13). 
Once the left ventricular hypertrophy has 
developed, which can be detected by the 
electrocardiograph, the prevalence of the left 
atrium size enlargement is high; 56% in female 
and 38% in male population (14). 
The left atrium enlargement developed in 
this manner with decreased “left atrium transport 
function“ may predispose arterial hypertension 
patients to develop atrial fibrillation, due to 
dispersion enlargement of effective refractory 
period of the left atrium (12). 
Left ventricular hypertrophy detected by 
electrocardiograph or by echocardiography is a 
significant risk factor in atrial fibrillation. 
In Framingham Heart group, the patients 
with left ventricular hypertrophy diagnosed by 
electrocardiograp had 3 to 3,8 times increased 
risk of atrial fibrillation development. 
The risk of atrial fibrillation development 
also increases by 28% per every 4 mm 
thickening of the left ventricular wall measured 
by ultrasound scanner (9). 
The ischemic heart disease, also associated 
with diastolic abnormalities and the increased 
filling pressures, leads to the left atrium 
enlargement, and as in hypertension and 
hypertensive heart disease, predisposes to atrial 
fibrillation (12). 
The arterial hypertension patients with 
concomitant ischemic heart disease had the 
highest average left atrium size value which is 
statistically more than in the group of arterial 
hypertension patients, those with left ventricular 
hypertrophy but without ischemia, and in the 
groups of patients with arterial hypertension but 
without left ventricular hypertrophy and without Acta Medica Medianae 2008,Vol.47                                        The size of the left atrium in patients with paroxy... 
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ischemia and the patients without arterial 
hypertension (LONE). 
Our finding corresponds to the statement 
that ischemic heart disease contributes to the left 
atrium enlargement, and especially it does 
contribute more if it is concomitant with arterial 
hypertension, as it is in our research. 
Myocardial ischemia is a significant 
complication of hypertensive heart disease, and it 
is the most common arrhythmic factor (5). 
In our research, the greatest percentage of 
patients with the left atrium enlargement was 
found in the group of arterial hypertension 
patients with concomitant ischemic heart disease, 
which is statistically more than in the group of 
arterial hypertension patients, those with left 
ventricular hypertrophy but without ischemia, 
and the group of arterial hypertension patients 
without left ventricular hypertrophy and without 
ischemia. 
Thus the finding proves that ischemic heart 
disease, concomitant with atrial hypertension, is 
the most common factor in the left atrium 
enlargement and atrial fibrillation genesis. 
Thanks to the Framingham Heart study, it 
was shown that among 4.731 patients who were 
subjected to the basic ultrasound scanner, the 
risk of atrial fibrillation development increased up 
to 39% per every 5 millimetres of left ventricular 
size enlargement after some other risk factors 
were taken into consideration (9). 
Our results are in accordance with the 
previous bibliography citations considering that 
the majority of repeated attacks were reported in 
the third group of patients, those with arterial 
hypertension and concomitant ischemic heart 
disease which had the highest average left atrium 
size value. That is statistically more significant 
when compared to the patients without arterial 
hypertension as well as with the patients with 
arterial hypertension but without left ventricular 
hypertrophy and without ischemia. 
Besides arterial hypertension, left ventri-
cular hypertrophy, ischemic heart disease, 
repeated atrial fibrillation attacks, the age of the 
patients could have an impact on the left atrium 
size. With advancing age and decreasing 
myocardial distension, as well as getting longer 
relaxation phase, the diastolic function becomes 
disturbed and that can cause the left atrium 
enlargement (15). 
In our research, the oldest patients had the 
highest average left atrium size value. These 
were the patients with arterial hypertension and 
concomitant ischemic heart disease, and they 
were, statistically speaking, much older 
compared to the patients without arterial 
hypertension (LONE).   
 
Conclusion 
 
Our research of the paroxysmal atrial fibrilla-
tion patients resulted in the following changes: 
1.The arterial hypertension patients with 
concomitant ischemic heart disease had the 
highest average left atrium size value which is, 
according to statistics, significantly higher than in 
the arterial hypertension patients without left 
ventricular hypertrophy and without ischemia as   
in the patients without arterial hypertension 
(LONE) and the arterial hypertension patients, 
those with left ventricular hypertrophy but 
without ischemia. Thus, a significant influence of 
ischemic heart disease concomitant with arterial 
hypertension on the left atrium enlargement is 
emphasized. 
2.The largest percentage of the patients 
with the enlarged left atrium is in the group of 
patients with arterial hypertension and 
concomitant  ischemic heart disease, which is, 
according to statistics, significantly more than in 
the group of patients with arterial hypertension   
without  left ventricular hypertrophy and without 
ischemia and in the group of patients with 
arterial hypertension with  left ventricular 
hypertrophy and without ischemia, which 
confirms that ischemic heart disease is a 
significant arrhythmic factor in comorbidity with 
arterial hypertension. 
3.The average left atrium size value in the 
arterial hypertension patients, those with left 
ventricular hypertrophy and without ischemia is, 
according to statistics, higher than in the arterial 
hypertension patients without left ventricular 
hypertrophy and without ischemia, and especially  
in the patients without arterial hypertension 
(LONE). Thus, the influence of the left ventricular 
hypertrophy on the left atrium size is particularly 
emphasized. 
4.The frequency of the enlarged left atrium 
in the arterial hypertension patients, those with   
left ventricular hypertrophy and without ischemia 
is statistically higher compared with the arterial 
hypertension patients without left ventricular 
hypertrophy and without ischemia, and 
particularly in the patients without arterial 
hypertension (LONE), who did not  have the 
enlarged left atrium. Thus, it is confirmed that 
left ventricular hypertrophy also stands for a 
significant arrhythmic factor. 
5.The repetition of atrial fibrillation attacks 
was mostly present in the patients with arterial 
hypertension and concomitant ischemic heart 
disease (the highest average left atrium size 
value), which is statistically significantly  higher 
compared to the patients without arterial 
hypertension (LONE) as well as compared to the 
patients with arterial hypertension but without 
left ventricular hypertrophy and without 
ischemia. The contribution and significance of 
repeated atrial fibrillation attacks on the left 
atrium enlargement was thus emphasized. 
6.The average age of the patients with 
arterial hypertension and concomitant heart 
disease (the highest average left atrium size 
value) is statistically higher when compared to 
the patients without arterial hypertension 
(LONE). Therefore, it can be  concluded that the 
age of the patients can also contribute to the left 
atrium  enlargement. 
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VELIČINA LEVE PRETKOMORE KOD BOLESNIKA SA PAROKSIZMALNOM 
ATRIJALNOM FIBRILACIJOM I ARTERIJSKOM HIPERTENZIJOM 
 
 
Radmila Stamenković i Milan Pavlović 
 
Atrijalna fibrilacija je česta supraventrikularna aritmija udružena sa arterijskom 
hipertenzijom. Mehanizmi kojim arterijska hipertenzija dovodi do nastanaka atrijalne 
fibrilacije su različiti i uključuju hipertrofiju leve komore, ishemiju miokarda, pogoršanu 
funkciju leve komore i uvećanje leve pretkomore. 
Cilj rada bio je utvrđivanje veličine leve pretkomore kod bolesnika sa paroksizmalnom 
atrijalnom fibrilacijom i arterijskom hipertenzijom. 
Istraživanjem je obuhvaćena populacija od 117 ispitanika sa paroksizmalnom 
atrijalnom fibrilacijom. Arterijsku hipertenziju imalo je 87 ispitanika, a 30 ispitanika činila 
je grupa bez arterijske hipertenzije i bez drugih poremećaja i bolesti (LONE). 
Ispitanici sa arterijskom hipertenzijom su podeljeni u tri grupe: ispitanici sa 
arterijskom hipertenzijom, bez hipertrofije leve komore i bez ishemije; ispitanici sa 
arterijskom hipertenzijom, hipertrofijom leve komore, bez ishemije; ispitanici sa 
arterijskom hipertenzijom i pridruženom ishemijskom bolešću srca. Ispitanici bez arterijske 
hipertenzije i bez drugih poremećaja i bolesti (LONE) predstavljaju četvrtu grupu. 
Veličina leve pretkomore određivana je ehokardiografski. Najveća prosečna vrednost 
veličine leve pretkomore dobijena je kod ispitanika sa arterijskom hipertenzijom i 
pridruženom ishemijskom bolešću srca 43,39 mm, potom kod ispitanika sa arterijskom 
hipertenzijom, hipertrofijom leve komore i bez ishemije 39,85 mm. Prosečna vrednost 
veličine leve pretkomore kod ispitanika sa arterijskom hipertenzijom, bez hipertrofije leve 
komore i bez ishemije bila je 37,24 mm, dok su najmanju prosečnu vrednost veličine leve 
pretkomore imali ispitanici bez arterijske hipertenzije (LONE) 34,61 mm. 
Uvećanu levu pretkomoru imalo je 80,95% ispitanika sa arterijskom hipertenzijom i 
pridruženom ishemijskom bolešću srca, a 45,45% ispitanika sa arterijskom hipertenzijom, 
hipertrofijom leve komore i bez ishemije. Ispitanici bez arterijske hipertenzije (LONE) nisu 
imali uvećanu levu pretkomoru.  
Zaključak je da veličina leve pretkomore u bolesnika sa arterijskom hipertenzijom u 
prisustvu hipertrofije leve komore, a posebno pridružene ishemijske bolesti srca predstavlja 
značajan preduslov za nastanak paroksizmalne atrijalne fibrilacije. Najveći procenat 
ispitanika sa uvećanom levom pretkomorom u grupi sa arterijskom hipertenzijom i 
pridruženom ishemijskom bolešću srca, dokazuje da je ishemijska bolest srca najčešći 
aritmogeni faktor. Hipertrofija leve komore je odmah iza nje. Acta Medica Medianae 
2008;47(3):5-10. 
 
Ključne reči: arterijska hipertenzija, hipertofija leve komore, uvećanje leve pretkomore, ishemija 
miokarda, paroksizmalna atrijalna fibrilacija. 